Fresenius Shares Slump After Novo Nordisk Kidney Disease Trial Shows Efficacy
By Mauro Orru
Shares of Germany's Fresenius and its dialysis-care business Fresenius Medical Care plunged Wednesday after Novo Nordisk said it would stop a trial to treat kidney failure in diabetes patients as it showed early signs of success, a development that could lower the number of dialysis patients.
At 0920 GMT, Fresenius Medical Care shares traded 19% lower at EUR32.10. Shares of Fresenius, which holds about 32% of Fresenius Medical Care, traded 12% lower at EUR24.43.
The Danish pharmaceutical giant said late Tuesday that it had decided to stop the trial early following a recommendation from an independent data monitoring committee due to early signs of efficacy. The trial started in 2019 to study the progression of kidney impairment and the risk of renal and cardiovascular mortality in people with type 2 diabetes and chronic kidney disease.
Novo Nordisk makes blockbuster weight-loss drugs Ozempic and Wegovy. Ozempic was originally developed to treat diabetes, but its use for weight loss has rapidly grown as both drugs share the same active ingredient, semaglutide, which works by mimicking a gut hormone called glucagon-like peptide-1, or GLP-1.
Citi analysts said that the early end of the trial would weigh on Fresenius and Fresenius Medical Care.
"We see kidney disease as one of the areas where GLP1s could potentially negatively impact the size of the relevant patient population over time," they wrote in a note to clients. "The early stopping of the FLOW trial indeed suggests such an impact."
Write to Mauro Orru at mauro.orru@wsj.com
(END) Dow Jones Newswires
October 11, 2023 05:38 ET (09:38 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
These Stocks Are (Still) Powering the Bull Market
-
5 Undervalued Energy Stocks to Play the AI Data Center Demand Boom
-
After Earnings, Is Lowe’s Stock a Buy, Sell, or Fairly Valued?
-
5 Stocks With the Largest Fair Value Estimate Cuts After Q1 Earnings
-
10 Stocks With the Largest Fair Value Estimate Increases After Q1 Earnings
-
Markets Brief: Inflation Back in the Spotlight
-
AI Is Booming, but Consumer Spending Is Slowing. Which Will Prevail in the Stock Market?
-
What’s Happening In the Markets This Week
-
3 Dividend Stocks for June 2024
-
After Earnings, Is Alibaba Stock a Buy, Sell, or Fairly Valued?
-
MongoDB Earnings: Slashing Valuation as Execution and Macro to Blame for Lower Guidance
-
Marvell Earnings: We Raise Our Medium-Term AI Forecast and Bring Our Valuation Up to $75
-
Zscaler Earnings: Impressive Traction in Emerging Products Drives Sales Growth for the Quarter
-
Dell Earnings: Raising Valuation on Strong AI, but the Stock Remains Severely Overvalued
-
After Earnings, Is Nvidia Stock a Buy, Sell, or Fairly Valued?
-
The 10 Best Companies to Invest in Now